论文部分内容阅读
目的:探讨脂必泰胶囊治疗老年人痰浊血瘀型高脂血症的临床疗效及安全性。方法:选取杭州市中医院2014年6月至2015年6月收治的老年原发性痰浊血瘀型高脂血症患者126例，采用随机数字表法分为对照组63例、观察组63例。对照组给予基础治疗加阿托伐他汀钙片；观察组在对照组的基础上，联合使用脂必泰胶囊。两组均连续治疗12周。观察两组临床疗效、中医证候积分、血脂、血液流变学指标，并记录两组患者的不良反应发生情况。结果:观察组总有效率为92.1%(58/63)，高于对照组的81.0%(51/63)，差异有统计学意义(χn 2＝8.199，n P<0.05)。治疗后，观察组中医证候积分为(9.31±1.78)分，低于对照组的(15.88±2.35)分，差异有统计学意义(n t＝17.689，n P<0.05)。治疗后，观察组血浆总胆固醇、甘油三脂、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇分别为(5.16±0.28)mmol/L、(1.89±0.21)mmol/L、(3.34±0.11)mmol/L、(1.18±0.13)mmol/L，对照组分别为(5.31±0.15)mmol/L、(2.22±0.20)mmol/L、(3.47±0.16)mmol/L、(1.11±0.12)mmol/L，两组差异均有统计学意义(n t＝3.748、9.032、5.314、3.140，均n P<0.05)。治疗后，观察组全血低切黏度、全血高切黏度、血浆黏度、纤维蛋白原分别为(10.68±2.38)mPa/s、(4.11±0.31)mPa/s、(1.33±0.22)mPa/s、(3.01±0.22)g/L，对照组分别为(11.55±2.39)mPa/s、(4.43±0.30)mPa/s、(1.61±0.25)mPa/s、(3.25±0.22)g/L，两组差异均有统计学意义(n t＝2.047、5.888、6.674、6.123，均n P0.05)。n 结论:脂必泰胶囊可以有效提高老年痰浊血瘀型高脂血症患者的临床疗效，改善中医证候，降低血脂，改善血液流变学参数，且无明显不良反应。“,”Objective:To investigate the clinical efficacy and safety of Zhibitai capsule in the treatment of senile hyperlipidemia patients with phlegm and blood stasis syndrome.Methods:From June 2014 to June 2015, 126 elderly patients with primary hyperlipidemia of phlegm and blood stasis syndrome admitted to Hangzhou Hospital of Traditional Chinese Medicine were randomly divided into control group and observation group, with 63 cases in each group.The patients in the control group were given basic treatment plus atorvastatin calcium tablets, and the patients in the observation group were treated with Zhibitai capsule on the basis of the control study.Both two groups received continuous treatment for 12 weeks.The clinical efficacy, TCM syndrome integral, blood lipid, hemorheology and adverse reactions of the two groups were observed.Results:The total effective rate in the observation group was 92.1%(58/63), which was higher than 81.0%(51/63) in the control group, and the difference was statistically significant(χn 2=8.199, n P<0.05). After treatment, the TCM syndrome score of the observation group was (9.31±1.78)points, which was lower than that of the control group[(15.88±2.35)points], and the difference was statistically significant(n t=17.689, n P<0.05). After treatment, the levels of total plasma cholesterol, triglyceride, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the observation group were (5.16±0.28)mmol/L, (1.89±0.21)mmol/L, (3.34±0.11)mmol/L and (1.18±0.13)mmol/L, respectively, which in the control group were (5.31±0.15)mmol/L, (2.22±0.20)mmol/L, (3.47±0.16)mmol/L and (1.11±0.12)mmol/L, respectively, the differences between the two groups were statistically significant(n t=3.748, 9.032, 5.314, 3.140, all n P<0.05). After treatment, the whole blood low shear viscosity, high shear viscosity, plasma viscosity and fibrinogen in the observation group were (10.68±2.38)mPa/s, (4.11±0.31)mPa/s, (1.33±0.22)mPa/s, (3.01±0.22)g/L, respectively, which in the control group were (11.55±2.39)mPa/s, (4.43±0.30)mPa/s, (1.61±0.25)mPa/s, (3.25±0.22)g/L, respectively, the differences between the two groups were statistically significant(n t=2.047, 5.888, 6.674, 6.123, all n P0.05).n Conclusion:Zhibitai capsule can effectively improve the clinical efficacy, improve TCM syndromes, reduce blood lipids and improve hemorheology parameters in elderly patients with hyperlipidemia syndrome of phlegm and blood stasis syndrome, with no obvious adverse reactions, which is worthy of clinical promotion.